• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Flyte Deploys Additional Vision Jets in the Northeast to Capture Surging Summer Demand

    4/28/26 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care
    Get the next $VTAK alert in real time by email

    Positioned to Meet Accelerating Travel Activity across New York City, The Hamptons, Nantucket and Martha's Vineyard

    Scalable Short-Haul Luxury Aviation Platform Targeting Key Regional Travel Markets

    FORT MILL, S.C., April 28, 2026 (GLOBE NEWSWIRE) -- Flyte, the regional air mobility subsidiary of Catheter Precision, Inc. (NYSE:VTAK) ("VTAK" or the "Company"), today announced the expansion of its Cirrus Vision Jet fleet ahead of peak summer demand, scaling short-haul service from New York City to East Hampton, Nantucket, Martha's Vineyard, Newport, and Cape Cod.

    The expansion targets one of the most concentrated luxury travel corridors in the United States, a set of routes where trips that can take three to six hours by car or ferry during peak summer traffic are typically 30 to 60 minutes on a Vision Jet.

    The move also comes as major airlines continue to retreat from short-haul flying, widening the gap in regional connectivity that Flyte's model is purpose-built to fill.

    "Demand across our core Northeast markets is accelerating as we head into peak season," said Marc Sellouk, CEO of Flyte. "Concentrated demand, repeat travel patterns, and limited efficient alternatives create a strong opportunity, and we are scaling the fleet to meet it."

    DEMAND DRIVERS SUPPORTING SCALE

    Management believes several underlying factors position Flyte for continued growth:

    • Concentrated Wealth and Multi-Residence Travel – A dense population of high-net-worth individuals regularly traveling between primary and secondary residences

    • Predictable, Repeat Travel Behavior - Consistent weekly and weekend movement between New York City and seasonal destinations supporting recurring usage and customer retention

    • Shift Toward Private Alternatives - With commercial short-haul airline service limited, combined with pricing pressure and operational challenges, travelers are driving increased interest in private aviation

    • Established Regional Airport Access - Northeast secondary airports support fast turnarounds, short ground times, and a premium passenger experience.

    PREMIUM EXPERIENCE DRIVING CUSTOMER ADOPTION

    Flyte is designed for customers who prioritize control, convenience, and experience. The platform addresses common commercial travel pain points, including security delays, schedule disruptions, and crowded terminals, by delivering a more direct and personalized travel experience.

    Management believes this value proposition supports strong repeat usage, high customer satisfaction, and increasing customer lifetime value over time.

    HIGH-VALUE ROUTES WITH SCALABLE OPPORTUNITY

    Flyte's initial focus includes high-demand corridors connecting New York City with:

    • East Hampton

    • Nantucket

    • Martha's Vineyard

    • Newport

    • Cape Cod

    Inter-destination travel between key summer markets is also expected to represent a significant opportunity, particularly among customers traveling between multiple residences.

    FRAGMENTED MARKET WITH SIGNIFICANT OPPORTUNITY

    The short-haul private aviation segment remains highly fragmented, with no clearly defined consumer-focused brand. Flyte is positioning itself to address this gap through a disciplined focus on operational execution, customer experience, and targeted route density.

    SCALING INTO PEAK SEASON

    With vision jets currently active and additional fleet expansion underway, the Company is aligning capacity to the highest-volume travel period of the year. The Company expects the expansion to drive meaningful increases in utilization and market share through the summer.

    "With additional Vision Jets coming online, we are ramping into peak demand and continuing to scale in an underserved, high-value market," added Sellouk.

    About Flyte

    Flyte is a technology-enabled regional air mobility company operating a growing fleet of Cirrus Vision Jets. Focused on short-haul markets, Flyte provides a faster and more efficient alternative to traditional private charter travel.

    Flight operations are conducted through Flyte's wholly owned subsidiary, Ponderosa Air, LLC, an FAA-certified Part 135 air carrier. With active operations and ongoing fleet expansion, Flyte is building a scalable aviation platform designed to serve underserved regional markets.

    For more information, visit www.flyte.travel

    About Catheter Precision

    Catheter Precision is an innovative U.S.-based medical device company developing advanced solutions to improve the treatment of cardiac arrhythmias. The Company focuses on bringing new technologies to market through physician collaboration and continuous product innovation.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements regarding future plans, expectations, and projections, are forward-looking and subject to risks and uncertainties that could cause actual results to differ materially. Forward-looking statements can be identified by words such as "believe," "anticipate," "may," "might," "can," "could," "continue," "depends," "expect," "expand," "forecast," "intend," "predict," "plan," "rely," "should," "will," "may," "seek," or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words.  These forward-looking statements include, but are not limited to, statements regarding our belief that the several underlying factors set forth above position Flyte for continued growth, our belief that our value proposition supports strong repeat usage, high customer satisfaction, and increasing customer lifetime value over time, our expectation that inter-destination travel between key summer markets represents a significant opportunity for us, particularly among customers traveling between multiple residences and our expectation that our continued expansion will drive meaningful increases in utilization and market share through the summer. These and other risks are detailed in the Company's filings with the Securities and Exchange Commission, including its most recent Forms 10-K and 10-Q. The Company undertakes no obligation to update any forward-looking statements except as required by law.

    Contacts

    Investor Relations

    973-691-2000

    IR@catheterprecision.com

    Media Relations

    flyte@elev8newmedia.com



    Primary Logo

    Get the next $VTAK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VTAK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VTAK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Flyte (VTAK) Makes Strategic Investment in Volato (SOAR)

    ATLANTA, June 08, 2026 (GLOBE NEWSWIRE) -- Flyte, the regional air mobility subsidiary of Catheter Precision, Inc. (NYSE:VTAK), focused on making private aviation more accessible and flexible for modern travelers, today announced that it has made a strategic investment in Volato Group, Inc. (NYSE:SOAR). As part of the transaction, VTAK acquired approximately 2.9 million shares of SOAR and will own approximately 7.5% of the company's outstanding common stock. This investment provides a basis to explore potential future collaboration to improve access, efficiency, and innovation across private aviation. "This strategic investment represents an exciting opportunity for both organizations,"

    6/8/26 10:43:33 AM ET
    $SOAR
    $VTAK
    Transportation Services
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care

    Volato Group Announces $2.2 Million Strategic Investment and AI Infrastructure Acquisition Focus

    Investment strengthens balance sheet as Company evaluates non-binding AI infrastructure and technology transaction opportunities Volato Group, Inc. (NYSE:SOAR) (the "Company" or "Volato"), a technology company focused on building scalable software and data solutions that improve the reliability and intelligence of high-stakes business decisions, today announced the signing of a definitive agreement to obtain a $2.2 million strategic investment lead by Catheter Precision, Inc. (NYSE:VTAK), and other institutional investors with experience investing in artificial intelligence and emerging technology companies. The investment of restricted common stock will strengthen Volato's balance shee

    6/8/26 6:15:00 AM ET
    $SOAR
    $VTAK
    Transportation Services
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care

    FLYTE ACTIVATES HIGH-FREQUENCY PREAKNESS FLIGHT PROGRAM, DEPLOYING FLEET TO SERVE STRONG NORTHEAST DEMAND

    Company Deploys Scalable Short-Haul Model Following Kentucky Derby to Monetize Peak Travel Window Flagship Routes from NYC, Boston, DC, and Philadelphia Positioned to Drive Immediate Revenue, High Utilization, and Dense Flight Activity NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Flyte, the regional air mobility subsidiary of Catheter Precision, Inc. (NYSE:VTAK) ("VTAK" or the "Company"), today announced the positioning of aircraft across the Northeast to support increased travel demand this coming weekend in anticipation of the Preakness Stakes on Saturday, May 16th. The program centers on Baltimore/Washington International Airport (BWI), the primary access point for race attendees, wit

    5/12/26 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $VTAK
    SEC Filings

    View All

    Catheter Precision Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Catheter Precision, Inc. (0001716621) (Filer)

    6/8/26 6:16:04 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Catheter Precision Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Catheter Precision, Inc. (0001716621) (Filer)

    5/18/26 4:17:11 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Catheter Precision Inc.

    10-Q - Catheter Precision, Inc. (0001716621) (Filer)

    5/18/26 7:22:56 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $VTAK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Jenkins David A

    4 - Catheter Precision, Inc. (0001716621) (Issuer)

    3/30/26 5:58:17 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Anderson Philip J

    4 - Catheter Precision, Inc. (0001716621) (Issuer)

    3/30/26 5:58:15 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Arno Andrew

    4 - Catheter Precision, Inc. (0001716621) (Issuer)

    3/30/26 5:58:11 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $VTAK
    Leadership Updates

    Live Leadership Updates

    View All

    Catheter Precision, Inc. Announces New Chief Financial Officer

    FORT MILL, SC / ACCESSWIRE / January 7, 2025 / Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced that it has brought on board Philip Anderson, to take on the position of Chief Financial Officer. Margrit Thomassen, who has been our Interim Chief Financial Officer, will continue with the company in the role of Controller.David Jenkins, CEO of Catheter Precision, commented on the hire, "After some time of searching for the right fit, we are happy to have concluded our search with Phil Anderson joining the team. His background includes executive management across a variety of industries, managing hedge fund

    1/7/25 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Catheter Precision, Inc. (NYSE American:VTAK) Presenting at the Sequire Investor Summit in Puerto Rico

    FORT MILL, SC / ACCESSWIRE / January 22, 2024 / Catheter Precision, Inc. (NYSE:VTAK), (the Company) a pioneering U.S. based medical device company committed to enhancing the well-being of patients with cardiac arrhythmias, is pleased to declare its participation in the forthcoming Sequire Investor Summit 2024. The eagerly awaited event, slated for January 23-25, 2024, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico, is poised to provide a spectrum of compelling opportunities for funds, companies, and investors.Puerto Rico has become a hub for family offices, funds, and affluent investors, thanks to its advantageous tax benefits. It stands out as one of the rare locations globally wh

    1/22/24 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $VTAK
    Financials

    Live finance-specific insights

    View All

    Catheter Precision Reports 2025 Results and Updates on Strategic Expansion

    Clinical, Commercial and Regulatory Milestones Achieved in 2025 Establish a Strong Foundation in Life Sciences as Revenue Increases 95% Year Over Year Acquisition of Flyte and Strengthened Capital Position Unlock Multi-Segment Growth Strategy with Multiple Near-Term Catalysts FORT MILL, S.C., March 31, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) ("VTAK" or the "Company"), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the fourth quarter and full year ended December 31, 2025 as well as certain other business updates. 2025: Execution Across Clin

    3/31/26 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    CRTD (Creatd Inc.) Sells Remaining 80% of Fly Flyte to NYSE-Listed VTAK (Catheter Precision Inc.), Securing Significant Cash and Equity Position

    NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB:CRTDD) today announced that it has sold its remaining 80% equity stake in its subsidiary, Fly Flyte, Inc. ("Flyte"), to Catheter Precision, Inc. (NYSE:VTAK). Under the terms of the completed transaction, Creatd will receive approximately $6,000,000 in cash and nearly $6,000,000 in Convertible Preferred Stock of VTAK. The NYSE-approved transaction considerably strengthens Creatd's balance sheet. The sale is consistent with Creatd's strategy of developing turnkey operating solutions that prepare businesses for listing on the public markets while simultaneously retaining a minority interest in them. The transaction positions Cr

    3/10/26 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    VTAK Acquires 20% Interest in Creatd's Subsidiary Fly Flyte, Inc.

    Strategic Partnership: Creatd expanded Fly Flyte's investor network by adding NYSE-listed VTAK as an investor in its subsidiary.Portfolio Expansion: Creatd continues advancing its portfolio strategy through multiple active acquisition discussions.Innovation in Aviation: Fly Flyte, Inc. is transforming regional aviation through accessibility, convenience, and technology-driven operations. NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB:CRTD) announced that Catheter Precision, Inc. (NYSE:VTAK) has acquired a 20% equity interest in Fly Flyte, Inc., its subsidiary, through a secondary purchase from an existing shareholder. The transaction aligns with Creatd's strategy of nurtu

    2/17/26 2:17:42 PM ET
    $CRTD
    $VTAK
    Publishing
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care

    $VTAK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Catheter Precision Inc.

    SC 13G/A - Catheter Precision, Inc. (0001716621) (Subject)

    11/14/24 5:12:56 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Catheter Precision Inc.

    SC 13G/A - Catheter Precision, Inc. (0001716621) (Subject)

    11/13/24 11:14:58 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Catheter Precision Inc.

    SC 13D/A - Catheter Precision, Inc. (0001716621) (Subject)

    10/30/24 5:26:20 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care